Unlock instant, AI-driven research and patent intelligence for your innovation.

Fully human influenza m2 specific antibodies

a technology of m2 and specific antibodies, applied in the field of human antibodies, can solve the problems of the same disadvantages, and achieve the effects of less severe side effects, high affinity, and high affinity

Inactive Publication Date: 2013-05-02
ELATOS GMBH
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a library-based screening that led to the identification of 53 human scFv that show high affinity to the extracellular domain of the influenza A M2 protein. These scFv were generated by combining different CDR sequences in their light chain variable regions (LCVRs) and heavy chain variable regions (HCVRs). The scFv were found to have different combinations of identical or highly similar CDR sequences in their LCVRs and HCVRs. The antibodies were found to have a high degree of binding to the M2 protein and were effective in treating and preventing influenza A virus infection in a mouse model. The antibodies were also found to have a therapeutic effect when administered as a single dose on day one or day two after infection. The CDR sequences of the LCVRs and HCVRs can be used to create a molecular fingerprint for the M2 protein, which can be used to identify different strains of influenza A virus. Overall, the patent text describes a novel group of human antibodies that target the M2 protein and have potential use in treating and preventing influenza A virus infection.

Problems solved by technology

Passive immunization with monoclonal antibodies (mAbs) targeting HA is very efficient, however, suffers the same disadvantages as the current vaccines due to antigenic shift and drift.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fully human influenza m2 specific antibodies
  • Fully human influenza m2 specific antibodies
  • Fully human influenza m2 specific antibodies

Examples

Experimental program
Comparison scheme
Effect test

example 1

Identification of M2-Specific Single-Chain Antibodies by Mammalian Cell Display

[0168]Peripheral blood mononuclear cells (PBMC) were isolated from 10 ml of heparinized blood of an individual with high M2-titers using the BD Vacutainer™ CPT™ Tube method (BD Biosciences, Franklin Lakes, N.J.). PBMC were pre-incubated with Alexa 647 nm-labeled Qβ (5.5 μg / ml) and human gamma globulin (11 μg / ml; Jackson ImmunoResearch) and then stained with: (1) an M2 extracellular domain consensus peptide (M2e; SEQ ID NO:48, cf. Table 7) coupled to Qβ (2.4 μg / ml) in combination with a Alexa 488 nm-labeled Qβ-specific mouse mAb (2 μg / ml), as well as a M2-specific mouse mAb (0.5 μg / ml) in combination with FITC-labeled donkey anti-mouse IgG antibody (1 μg / ml; Jackson ImmunoResearch); (2) PE-labeled mouse anti-human IgM (diluted 1:50; BD Biosciences / Pharmingen), mouse anti-human IgD (diluted 1:100; BD Biosciences / Pharmingen), mouse anti-human CD14 (diluted 1:50; BD Biosciences / Pharmingen), and mouse anti-hum...

example 2

Gene Rescue, ELISA Screening and Sequencing of M2-Specific Antibodies

[0170]The supernatants of BHK cells encoding putative M2e-specific antibodies, each containing a monoclonal recombinant Sindbis virus, were subjected to RT-PCR as described (see WO 2008 / 055795 A1). The resulting PCR products, each comprising a scFv coding region, were digested with the restriction endonuclease Sfi1 and cloned into the expression vector pCEP-SP-Sfi-Fc (disclosed as SEQ ID NO:37 in WO 2008 / 055795 A1), allowing for expression of scFv proteins fused to a C-terminal human Fc-γ1 domain under the control of a CMV promoter.

[0171]For ELISA analysis, each of the clones was transfected into HEK-293T cells in a 24-well plate format, using Lipofectamine 2000 (Invitrogen) according to the manufacturer's recommendations. 2-3 days post transfection, supernatants containing transiently expressed scFv-Fc fusion proteins were harvested. To check for M2e-specific binding, ELISA plates were coated with M2e-conjugated R...

example 3

Expression and Purification of M2-Specific scFv-msFcγ2c Fusion Proteins

[0174]To investigate the effect of M2e-specific human antibodies on Influenza A infection in a mouse model, clones D005, E040 and F052 were expressed and purified as scFv-mouse Fc-γ2c (msFcγ2c) fusion proteins. The nucleotide sequences encoding the D005, E040 and F052 scFv-mouse Fc-γ2c (msFcγ2c) fusion proteins correspond to SEQ ID NOs:42, 44 and 46, respectively. The amino acid sequences of the D005, E040 and F052 scFv-mouse Fc-γ2c (msFcγ2c) fusion proteins correspond to SEQ ID NOs: 43, 45 and 47, respectively. The corresponding scFv coding regions were excised from the pCEP-SP-Sfi-Fc expression vectors with the restriction endonuclease Sfi1 and the resulting fragments were cloned into the expression vector pCEP-SP-Sfi-msFcγ2c (SEQ ID NO:41). The Sfi-digested fragments of monoclonal antibodies D005, E042, and F052 correspond to SEQ ID NOs 38, 39 and 40, respectively. These Sfi-fragments encode the entire scFv fr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
dissociation constantaaaaaaaaaa
dissociation constantaaaaaaaaaa
dissociation constantaaaaaaaaaa
Login to View More

Abstract

The present invention relates to human antibodies, preferably to fully human antibodies, which are specifically binding to influenza M2e antigen. The invention further relates to individual light- and / or heavy chains of such antibodies, to nucleic acids encoding said antibodies or their light- and / or heavy chain, and to expression vectors for the expression of said antibodies. Furthermore, the invention relates to the use of said antibodies in the treatment and / or prevention of influenza A virus infection, preferably in humans.

Description

RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No. 13 / 132,658, filed Jun. 3, 2011, which is a national stage filing under 35 U.S.C. §371 of international application PCT / EP2009 / 066052, filed Nov. 30, 2009, which was published under PCT Article 21(2) in English, and claims priority to EP 09173548, filed Oct. 20, 2009 and EP 08170749, filed Dec. 4, 2008.FIELD OF THE INVENTION[0002]The present invention relates to human antibodies, preferably to fully human antibodies, which are specifically binding to influenza M2e antigen. The invention further relates to individual light- and / or heavy chains of such antibodies, to nucleic acids encoding said antibodies or their light- and / or heavy chain, and to expression vectors for the expression of said antibodies. Furthermore, the invention relates to the use of said antibodies in the treatment and / or prevention of influenza A virus infection, preferably in humans.RELATED ART[0003]Influenza A virus still is...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/10
CPCA61K2039/505C07K16/1018C07K2316/96C07K2317/21C07K2317/92C07K2317/56C07K2317/565C07K2317/622C07K2317/732C07K2317/34A61P31/16C07K2317/76
Inventor BACHMANN, MARTIN F.BAUER, MONIKABEERLI, ROGERSCHMITZ, NICOLE
Owner ELATOS GMBH